Trials / Completed
CompletedNCT04635631
STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
AN OPEN-LABEL, SINGLE-ARM, PHASE 1 STUDY OF PHARMACOKINETICS, SAFETY AND ANTI-TUMOR ACTIVITY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase1 study to evaluate the PK (single dose and multiple doses) and safety of talazoparib 1 mg Once Daily in Chinese adult participants with advanced solid tumors. A maximum of approximately 15 participants will be enrolled such that approximately 12 evaluable participants complete the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | talazoparib | Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days. |
Timeline
- Start date
- 2020-11-30
- Primary completion
- 2021-08-08
- Completion
- 2021-12-14
- First posted
- 2020-11-19
- Last updated
- 2023-10-10
- Results posted
- 2023-10-10
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04635631. Inclusion in this directory is not an endorsement.